



---

## MANAGEMENT REPORT OF FUND PERFORMANCE

---

**Big Pharma Split Corp.**

**December 31, 2021**



The Fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure, can be obtained at your request, and at no cost, by calling us at 1-866-998-8298; by writing to us at Harvest Portfolios Group Inc., 610 Chartwell Road, Suite 204, Oakville, Ontario, L6J 4A5; by visiting our website at [www.harvestportfolios.com](http://www.harvestportfolios.com); or on SEDAR at [www.sedar.com](http://www.sedar.com).

# Big Pharma Split Corp.

## CORPORATE OVERVIEW

Harvest Portfolios Group Inc. (“Harvest” or the “Manager”) is a Canadian Investment Manager founded in 2009. Harvest is focused on developing investment products that follow three investment criteria.

We (i) endeavor to develop investment products that are clear in their mandate and easy for investors to understand, (ii) strive to be transparent so that our investors can review their financial reports and know exactly what they own and (iii) seek to provide investors with consistent monthly or quarterly income by investing the fund portfolios in well managed companies that have a steady cash flow and dividend-paying history.

## INVESTMENT PRODUCT

Big Pharma Split Corp. (the “Company” or “Fund”) will invest in an initially equally-weighted portfolio (the “Portfolio”) comprised of Equity Securities<sup>1</sup> of ten issuers, selected by the Portfolio Manager<sup>1</sup> from the Investable Universe<sup>1</sup>, that at the time of investment and immediately following each semi-annual reconstitution and rebalancing: (i) are listed on a North American exchange; (ii) pay a dividend; and (iii) have options in respect of its Equity Securities that, in the opinion of the Portfolio Manager, are sufficiently liquid to permit the Portfolio Manager to write options in respect of such securities. The Portfolio will be comprised primarily of the largest (as determined by market capitalization calculated in US\$) Pharmaceutical Issuers<sup>1</sup> in the Investable Universe.

---

<sup>1</sup> As defined in the Fund’s Short Form Base Shelf Prospectus dated November 4, 2020.

# Big Pharma Split Corp.

## PRESIDENT'S MESSAGE

### Unitholder letter March 2022

#### Dear Valued Investor,

Thank you for placing your trust and confidence in Harvest's investment philosophy through 2021. It is a philosophy that held strong in our ETFs and funds in the past year, and one we will remain committed to in 2022.

As you know, at Harvest Portfolios Group Inc., we are equity investors. All our products are either equity income funds or equity growth focused funds. This is by design in order to take advantage of the long-term growth of capital markets, the growth of industries and the growth of well positioned and managed companies.

Since the dawn of the industrial age, businesses have accounted for the great majority of wealth creation around the world. Regardless of all the disruption that has occurred over the last 300 years, the surge and implementation of ideas and innovation has advanced humanity to higher living standards and longer life spans.

Wealth is not created in subdued societies or by government handouts. It is created in free and open markets where creative people can build their ideas and dreams into global businesses. We are surrounded by these visionary individuals and companies, and we celebrate their innovation continuously.

At Harvest, we invest in those long-term, growth-oriented, industries and mega-trends that show great promise and the signs of progressive change. We aim to select the best businesses in those industries. Businesses with track records of success, solid management teams, and earnings growth.

As a unitholder, you own one of our Harvest ETFs, mutual funds, or market traded closed end funds. That means many of you very likely experienced good returns over 2021. It was a surprisingly good year for markets, returns were well above the norm for most equity markets. Though it was a very enjoyable rise, we expect to see markets trend back into their longer-term norms which fall roughly in the 8%-10% range, depending on which time period you use.

It is in moments like these when your trust in our philosophy proves its value. If you own quality equities, those longer-term returns will provide ample compound growth for your future needs. If you are retired or planning to retire soon, a basket of quality equities generating an attractive distribution is positioned to help grow your capital over time and supplement your income.

As an investor, you will always have to deal with market noise. Currently, that noise is focused on levels of inflation and potentially higher interest rates.

We agree that current inflation levels are running higher than normal, due to a slowdown in production in many industries, a shortage of readily available workers at all levels of manufacturing and services, and disruptions in logistics and delivery systems. This is occurring in a period of much higher demand than was anticipated early in 2021.

Inflation pressure is not just a Canadian or North American issue, it is global in nature and will take time to right itself. This "demand" inflation is creating pressure on Central Banks to step up interest rates in order to tame the potential of it getting out of control.

While interest rate increases may be on the horizon, we believe fewer should be expected. What we are facing can be described as acute symptoms, not a chronic condition. Prior to the pandemic, longer term trends exhibited a pattern of declining inflation. We believe that those conditions still exist, they are just obscured in the current environment.

At Harvest, we make investment decisions based on industry and business fundamentals. We would not let a potential change in interest rate policy influence our decisions. Those types of short-term factors are for traders. We are not traders, we are investors.

As we look ahead to 2022, we remain steadfast in our philosophy of choosing long term growth industries or mega-trends. Our outlook on these mega trends is framed by our orientation towards high quality companies and long-term trends.

Where growth areas like travel or blockchain may be considered themes by some, we view them quite differently. We see the well-established, long-term growth trajectory of the travel industry. We see the fast adoption of efficient and digitally secure blockchain technology. We see these and our other funds as positions or proxies on long term growth for these industries and mega-trends.

## Big Pharma Split Corp.

Choose the industry first, choose where you think the puck is going, then drill down and start to find the standout businesses that can expand in those industries. That is how we approach investing.

Investing is not static and we have to fine tune and make changes from time to time. In general, when we take a position, it is to hold for the longer term. That could mean holding a position for 5 years or more especially, in our equity income funds.

Let me again thank you for your support and confidence in the Harvest team and our products. Let me assure you that we will remain steadfast in our management and development of products to meet the needs of investors for both income and growth.

Sincerely,

*Signed* "Michael Kovacs"

Michael Kovacs,

President and Chief Executive Officer

# Big Pharma Split Corp.

## MANAGEMENT DISCUSSION OF FUND PERFORMANCE

The annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the Fund. For your reference, the annual financial statements of the Fund are attached to the annual management report of fund performance. You may obtain additional copies of these documents at your request, and at no cost, by calling toll free at 1-866-998-8298; by writing to us at Harvest Portfolios Group Inc., 610 Chartwell Road, Suite 204, Oakville, Ontario, L6J 4A5; or by visiting our website at [www.harvestportfolios.com](http://www.harvestportfolios.com); or on SEDAR at [www.sedar.com](http://www.sedar.com).

Unitholders may also contact us using one of these methods to request a copy of the Fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

## INVESTMENT OBJECTIVES AND STRATEGY

The Fund has been created to provide investors with a unique exposure to a portfolio of Equity Securities of ten issuers, selected by the Portfolio Manager from the Investable Universe, that at the time of investment and immediately following each semi-annual reconstitution and rebalancing: (i) are listed on a North American exchange; (ii) pay a dividend; and (iii) have options in respect of its Equity Securities that, in the opinion of the Portfolio Manager, are sufficiently liquid to permit the Portfolio Manager to write options in respect of such securities. The Portfolio will be comprised primarily of the largest (as determined by market capitalization calculated in US\$) Pharmaceutical Issuers in the Investable Universe.

The investment objectives for the Preferred shares are to provide their holders with fixed cumulative preferential quarterly cash distributions in the amount of \$0.125 per Preferred share (\$0.50 per annum or 5.0% per annum on the issue price of \$10.00 per Preferred share) until December 31, 2022 (the "Maturity Date") and to return the original issue price of \$10.00 to holders on the Maturity Date.

The investment objectives for the Class A shares are to provide their holders with regular monthly non-cumulative cash distributions targeted to be \$0.1031 per Class A share representing a yield on the issue price of the Class A shares of 8.25% per annum on the issue price of \$15.00 per Class A share and to provide holders with the opportunity for growth in the net asset value per Class A share.

To achieve its investment objectives, the Company will invest in an initially equally-weighted Portfolio comprised of Equity Securities of ten issuers from the Investable Universe, eight of which will be selected by the Portfolio Manager from the ten largest (as determined by market capitalization calculated in US\$) Pharmaceutical Issuers in the Investable Universe and the remaining two issuers will be selected by the Portfolio Manager from the Investable Universe.

Harvest will semi-annually reconstitute and rebalance the Portfolio.

## RISK

The risks associated with investing in the Fund are as described in the prospectus. There were no material changes to the Fund over the period that affected the overall level of risk of the Fund.

## RESULTS OF OPERATIONS

The Fund's Class A and Preferred shares returned 23.13% and 5.09%, respectively, compared to the MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD) benchmark return of 21.46% for the year ended December 31, 2021.

The three primary long-term drivers for the healthcare sectors remain unchanged: Aging populations, technological innovation (devices and drugs) and growth from developing markets, where there is a disproportionate share of increased wealth expended on healthcare needs. These medium to longer term drivers remain in-tact and form the basis of our longer-term positive view on the sector. Over the past several years, the sector has had several headwinds driven in large part by sentiment towards the sector that has been muted driven by the political rhetoric in the United States as they grapple with rising out of pocket healthcare expenditures.

There have been several positive shorter-term factors that we believe have improved the sentiment and attractiveness of the sector since prior to the onset of the pandemic in 2020. Firstly, the fact that Joe Biden became President of the United States has significantly reduced the extreme political rhetoric seen pre-election through-out 2019. The Democratic Party's policy initiatives are seen to be centrist with potential outcomes well known. Proposed policy initiatives that were included in the Build Back Better stimulus bill were also seen to have marginal impact to the sector although approval of the package remained outstanding early through the first quarter. This, coupled with the immediate response by the healthcare and specifically pharmaceuticals industry to mobilize significant financial and human capital quickly and efficiently highlights their commitment to finding treatments and potential vaccines. This has improved the public perception and investor sentiment and has started to result in valuation metrics improving relative to the broader market. Lastly, pharmaceuticals are known for

## Big Pharma Split Corp.

their superior good status and has often performed well during uncertain times. Particularly for the drug manufacturers, the necessity of their goods during robust economic times and during recessions, provides for some insights and clarity into the financial performance over the near to medium term.

During the year, there were many gyrations in several areas of the broader market and across investing styles with media commenters highlighting the shift from growth to value investing and out of momentum into cyclicals. These market gyrations continued through the back half of the year and into early 2022 as the macro narrative shifted towards supply chain issues while inflationary pressures that were thought to be transient have remained elevated. This has increased the uncertainty around interest rate policies in the United States and has also increased the prospects of the Federal Funds rate being raised significantly higher in 2022. This, coupled with heightened geopolitical tensions has resulted in some uncertainty and exacerbated some of the rotations seen throughout 2021. Specifically in pharmaceuticals, as they tend to have some value style characteristics and benefited as that style was at times favoured over traditionally high growth equities. The shorter-term visibility into the underlying businesses, attractive valuations, improved investor sentiment and political climate, coupled with the long term structurally positive macro drivers, lay the foundation for our positive outlook for the sector.

The Fund was invested in 8 out of the 10 largest pharmaceutical companies and 2 large capitalization biotechnology companies and wrote call options to meet its income objectives.

### RECENT DEVELOPMENTS

The spread of the coronavirus (“COVID-19”) has caused volatility in the global financial markets and impacted the global economy. The ongoing emergence of variants continue to add uncertainty to the global economy. Although financial markets have been strong over the past year, this uncertainty may have an impact on the financial performance of the Fund's investments and the Fund's future investment results may be materially adversely affected.

On March 4, 2021, the Fund completed a secondary offering and raised a total of \$9.3 million (before fees and issue costs) issuing an additional 385,200 Class A shares at \$13.75 per share and 385,200 Preferred shares at \$10.50 per share.

On June 7, 2021, the Fund announced commencement of an at-the-market equity program (the “ATM Program”) which allows the Fund to issue shares to the public from time to time, at the Fund's discretion. Any Class A shares or Preferred shares sold in the ATM Program will be sold through the Toronto Stock Exchange or any other marketplace in Canada on which the Class A shares and Preferred shares are listed, quoted or otherwise traded at the prevailing market price at the time of sale.

During the period ended December 31, 2021, 166,300 Class A shares were issued under the ATM Program at an average selling price of \$13.70 per Class A share. Gross proceeds, net proceeds and commissions on the Class A shares issued were \$2,277,946, \$2,267,098 and \$10,848, respectively.

During the period ended December 31, 2021, 166,300 Preferred shares were issued under the ATM Program at an average selling price of \$10.23 per Preferred share. Gross proceeds, net proceeds and commissions on the Preferred shares issued were \$1,701,925, \$1,667,214 and \$34,711, respectively.

### RELATED PARTY TRANSACTIONS

There were no related party transactions during the reporting period, except for management fees and other expense reimbursements paid to Harvest, as noted below in Management and Other Fees.

### MANAGEMENT AND OTHER FEES

The Fund pays the Manager a management fee calculated based on the average daily net asset value (“NAV”) and paid monthly in arrears, based on an annual rate of 0.75%, plus applicable taxes, of the NAV of the Fund. For these purposes, the Preferred shares are not considered a liability of the Fund. At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

#### Operating expenses

The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of shares, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee (“IRC”), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

## Big Pharma Split Corp.

### **Other expenses**

The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to shareholders and other shareholder communications; a reasonable allocation of salaries and benefits; and other administrative expenses and costs incurred in connection with the Fund's ongoing operations. These expenses were \$14,184 for the year ended December 31, 2021 (2020 - \$18,340) and are included in the shareholder reporting costs on the Statements of Comprehensive Income (Loss) in the financial statements.

### **Waivers and absorptions**

At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. There were no management fee waivers or expense absorptions for the year ended December 31, 2021 or 2020. The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

### **Issue costs**

Certain Offering expenses such as costs of creating the Fund, the cost of printing and preparing the prospectus, legal expenses of the Fund, agent's fees payable by the Fund, out-of-pocket expenses incurred by the agents as well as brokerage commissions charged on trades under the ATM program are included in the carrying amount of the Fund's obligation for net assets attributable to holders of redeemable Class A shares. As a result of the priority of the Preferred shares, the expenses of the Offering will effectively be borne by holders of the Class A shares (as long as the net asset value per unit exceeds the Offering price per Preferred share plus accrued and unpaid distributions) and the net asset value per Class A share will reflect the expenses of the Offering of both the Preferred shares and Class A shares.

### **RECOMMENDATIONS OR REPORTS BY THE INDEPENDENT REVIEW COMMITTEE**

The Independent Review Committee tabled no special reports and made no extraordinary material recommendations to management of the Fund during the year ended December 31, 2021.

# Big Pharma Split Corp.

## FINANCIAL HIGHLIGHTS

The following tables present selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the year ended December 31, 2021 and past annual periods. This information is derived from the Fund's annual audited financial statements.

### Class A shares

THE FUND'S NET ASSETS PER SHARE	2021	2020	2019	2018	2017
<b>Net assets - beginning of the year<sup>2</sup></b>	\$ 14.11	\$ 15.41	\$ 14.05	\$ 13.73	\$ 13.65
<b>Increase (decrease) from operations</b>					
Total revenue	0.59	0.83	0.67	0.77	0.02
Total expenses	(0.49)	(0.42)	(0.41)	(0.54)	(0.08)
Preferred share distribution	(0.53)	(0.48)	(0.47)	(0.50)	(0.05)
Preferred shares agent fees and issue costs	(0.15)	-	-	-	(0.42)
Premium (discount) on issuance of preferred shares	0.18	-	-	-	-
Realized gains (losses) for the year	(0.01)	2.21	1.43	(0.09)	(0.07)
Unrealized gains (losses) for the year	3.68	(2.36)	0.94	1.92	0.37
<b>Total increase (decrease) from operations<sup>1</sup></b>	<b>\$ 3.27</b>	<b>\$ (0.22)</b>	<b>\$ 2.16</b>	<b>\$ 1.56</b>	<b>\$ (0.23)</b>
<b>Distributions<sup>3</sup></b>					
Dividends	(0.21)	(1.24)	(1.24)	(1.24)	(0.10)
Capital gain	(1.75)	-	-	-	-
<b>Total annual distributions<sup>3</sup></b>	<b>\$ (1.96)</b>	<b>\$ (1.24)</b>	<b>\$ (1.24)</b>	<b>\$ (1.24)</b>	<b>\$ (0.10)</b>
<b>Net assets - end of the year<sup>1</sup></b>	<b>\$ 15.07</b>	<b>\$ 14.11</b>	<b>\$ 15.41</b>	<b>\$ 14.05</b>	<b>\$ 13.73</b>

RATIOS AND SUPPLEMENTAL DATA	2021	2020	2019	2018	2017
<b>Total net asset value (including Preferred shares)</b>	<b>\$ 37,266,557</b>	<b>\$ 22,532,916</b>	<b>\$ 26,891,373</b>	<b>\$ 32,251,925</b>	<b>\$ 32,276,788</b>
<b>Total net asset value – Class A shares</b>	<b>\$ 22,403,907</b>	<b>\$ 13,185,266</b>	<b>\$ 16,309,493</b>	<b>\$ 18,842,925</b>	<b>\$ 18,676,788</b>
Number of Class A shares outstanding	1,486,265	934,765	1,058,188	1,340,900	1,360,000
Management expense ratio – Class A shares <sup>4</sup>	8.36%	6.28%	6.45%	6.48%	17.82%
Management expense ratio before waivers or absorptions – Class A shares <sup>4</sup>	8.36%	6.28%	6.45%	6.48%	17.82%
Trading expense ratio <sup>5</sup>	0.15%	0.17%	0.18%	0.18%	0.58%
Portfolio turnover rate <sup>6</sup>	31.33%	45.91%	45.06%	50.21%	3.33%
<b>Net asset value per unit</b>	<b>\$ 25.07</b>	<b>\$ 24.11</b>	<b>\$ 25.41</b>	<b>\$ 24.05</b>	<b>\$ 23.73</b>
<b>Net asset value per Class A shares</b>	<b>\$ 15.07</b>	<b>\$ 14.11</b>	<b>\$ 15.41</b>	<b>\$ 14.05</b>	<b>\$ 13.73</b>
<b>Net asset value per Preferred shares</b>	<b>\$ 10.00</b>	<b>\$ 10.00</b>	<b>\$ 10.00</b>	<b>\$ 10.00</b>	<b>\$ 10.00</b>
<b>Closing market price – Class A shares</b>	<b>\$ 14.67</b>	<b>\$ 13.40</b>	<b>\$ 14.05</b>	<b>\$ 12.38</b>	<b>\$ 14.15</b>
<b>Closing market price – Preferred shares</b>	<b>\$ 10.60</b>	<b>\$ 10.68</b>	<b>\$ 10.48</b>	<b>\$ 10.17</b>	<b>\$ 10.30</b>

### Explanatory Notes:

- Net assets and distributions are based on the actual number of shares outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of shares outstanding over the reporting period. It is not intended that the Fund's net assets per share table act as a continuity of opening and closing net assets per Class A share.
- Net assets, at the commencement of operations on November 24, 2017 was \$13.65, net of agents' commissions and issuance costs of \$1.35 per share.



## Big Pharma Split Corp.

3. Distributions were paid in cash.
4. Management expense ratio ("MER") is based on total expenses (excluding commissions and other portfolio transaction costs) of the stated period and is expressed as an annualized percentage of the Class A daily average net asset value during the period. The MER for the period December 31, 2017 includes agent fees of \$1,428,000, issue costs of \$408,000 and Preferred share distributions of \$70,217. Agent fees and issues costs are treated as one-time expenses and therefore were not annualized. The MER without these costs and excluding the Preferred share distribution was 4.47%. The MER without agent fees and issue costs but including the Preferred share distribution was 8.06%. The MER based on the daily average of the total net asset value (including Preferred shares) is 10.34%. This MER includes agent fees, issue costs and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 2.59%. The MER without agent fees and issue costs but including the Preferred share distribution was 4.67%.

The Class A MER for the year ended December 31, 2018 excluding the Preferred share distribution was 2.91%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.78%. This MER excluding the Preferred share distribution was 1.69%.

The Class A MER for the year ended December 31, 2019 excluding the Preferred share distribution was 2.94%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.66%. This MER excluding the Preferred share distribution was 1.67%.

The Class A MER for the year ended December 31, 2020 excluding the Preferred share distribution was 2.80%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.65%. This MER excluding the Preferred share distribution was 1.63%.

The Class A MER for the year ended December 31, 2021 includes agent fees of \$359,681, issue costs of \$119,421, accretion of premium on issuance of Preferred shares of \$231,526 and Preferred share distributions of \$687,381. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.26%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 7.01%. The MER based on the daily average of the total net asset value (including Preferred shares) was 4.91%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.91%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 4.12%.

5. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value (including preferred shares) during the period. In 2020 the calculation was modified to include certain transaction costs charged by the custodian. The trading expense ratio in prior periods was not re-stated.
6. The Fund's portfolio turnover rate indicates how actively the Fund's portfolio advisor manages its portfolio investments. A portfolio turnover of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher a Fund's portfolio turnover rate, the greater the trading costs payable by the Fund and the greater the chance of an investor receiving taxable capital gains. There is not necessarily a relationship between a high turnover rate and the performance of a Fund.

# Big Pharma Split Corp.

## Past Performance


The performance information presented herein assumes all dividends of the Fund during the periods presented were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemptions, or other charges that would have reduced returns or affected performance. Past performance of the Fund is not necessarily indicative of how it will perform in the future.

## YEAR-BY-YEAR RETURNS

The following charts present the Fund's performance for each of the years shown and illustrate how the Fund's performance varied for Class A and Preferred shares. The charts show, in percentage terms, how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year.


### Fund Performance

#### Class A shares



2017 represents the period from November 24 to December 31

#### Preferred shares



2017 represents the period from November 24 to December 31

# Big Pharma Split Corp.

## ANNUAL COMPOUND RETURNS

The following table shows the annual compound returns for the Fund. All returns are in Canadian dollars, on a total return basis, net of fees.

For comparison purposes the MSCI Daily Total Return World Gross Pharmaceuticals Local Index (USD) (the "Index") is used. While the Fund uses this benchmark for long-term performance comparisons, it is not managed relative to the composition of the Index. As a result, the Fund may experience periods when its performance is not aligned with the Index, either positively or negatively. The return of the Index is calculated without the deduction of management fees and fund expenses whereas the performance of the Fund is calculated after deducting such fees and expenses. Please see the "Results of Operations" section of this report for a discussion on recent performance.

Investment Return %	1 Year	3 Years	5 Years	10 Years	Since Inception
Class A share Performance	23.13	14.06	-	-	13.51
Preferred share Performance	5.09	5.09	-	-	5.10
MSCI World Pharmaceuticals Gross Total Return Local Index (USD)	21.46	14.44	-	-	11.67

## SUMMARY OF INVESTMENT PORTFOLIO

The major portfolio categories and top holdings of the Fund at the end of the period are indicated in the following tables. A detailed breakdown of the Fund's holdings is available in the "Schedule of Investments" section of the Fund's financial statements.

As at December 31, 2021

Top Holdings	% of Net Asset Value
Pfizer Inc.	19.5
AbbVie Inc.	17.5
Eli Lilly and Company	16.9
AstraZeneca PLC ADR	15.4
Johnson & Johnson	14.9
Novartis AG ADR	14.9
Amgen Inc.	14.8
Bristol-Myers Squibb Company	14.6
Merck & Co., Inc.	14.6
Sanofi ADR	14.5
Cash and other assets and liabilities	6.0
Foreign currency forward contracts	3.6
Options	(0.9)
Preferred shares	(66.3)
<b>Total</b>	<b>100.0</b>

This summary of investment portfolio may change due to the ongoing portfolio transactions of the Fund. Quarterly updates of the Fund's investment portfolio are available from Harvest Portfolios Group Inc. at [www.harvestportfolios.com](http://www.harvestportfolios.com).

# Big Pharma Split Corp.

## SECTOR ALLOCATION

<b>Sector</b>	<b>% of Net Asset Value</b>
Health Care	157.6
Cash and other assets and liabilities	6.0
Foreign currency forward contracts	3.6
Options	(0.9)
Preferred shares	(66.3)
<b>Total</b>	<b>100.0</b>

## GEOGRAPHIC ALLOCATION

<b>Country of Risk</b>	<b>% of Net Asset Value</b>
United States	112.8
United Kingdom	15.4
Switzerland	14.9
France	14.5
Cash and other assets and liabilities	6.0
Foreign currency forward contracts	3.6
Options	(0.9)
Preferred shares	(66.3)
<b>Total</b>	<b>100.0</b>



### **Head Office**

610 Chartwell Road, Suite 204  
Oakville, Ontario L6J 4A5

Phone Number: 416.649.4541

Toll Free: 866.998.8298

Fax Number: 416.649.4542

Email: [info@harvestportfolios.com](mailto:info@harvestportfolios.com)

---

#### **CAUTION REGARDING FORWARD-LOOKING STATEMENTS**

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in the Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.